Predict your next investment

Corporation
zenyaku.co.jp

See what CB Insights has to offer

Investments

4

Partners & Customers

1

About Zenyaku Kogyo

Zenyaku Kogyo Co., Ltd. The company was founded in 1950 and is based in Tokyo, Japan. Zenyaku Kogyo Co., Ltd develops self-medication drugs. It offers its products through pharmacies and drugstores.

Zenyaku Kogyo Headquarter Location

6-15 5-chome Otsuka, Bunkyo-ku

Japan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zenyaku Kogyo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Zenyaku Kogyo in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Zenyaku Kogyo News

Worldwide Microscopic Polyangiitis Industry to 2030 - Featuring Genentech, Zenyaku Kogyo and Teijin Pharma Among Others - ResearchAndMarkets.com

May 20, 2021

May 20, 2021 10:28 AM Eastern Daylight Time This report deliver an in-depth understanding of the MPA, historical and forecasted epidemiology as well as the MPA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. The MPA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM MPA market size from 2018 to 2030. The report also covers current MPA treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. Key Findings In 2020, the total incident cases of MPA were found out to be 5,196 in the 7MM. As per the estimates by the publisher, these cases are expected to decrease at a CAGR of -0.02%, for the study period of 2018-2030. As the major contributor to the incident population are Japan (population growth rate, -0.4%) and Germany (population growth rate, -0.3%) where the population is declining, hence there is a decrease in the incident cases of MPA also. As per estimates, Japan had the highest incident cases of MPA (2,280), and among the EU5, Germany had the highest incident cases (1,041), followed by the UK (387), in 2020. In 2020, 660 incident cases were observed in the males, whereas 325 incident cases were observed in females in the US. The market size of Microscopic Polyangiitis (MPA) in the 7MM was estimated to be USD 31 million in 2020. According to the estimates, in 2020, the highest market size of Microscopic Polyangiitis (MPA) was found in Japan (USD 11 million), followed by the US (USD 10 million). The market size of rituximab and steroids in seven major markets was USD 16.1 million and USD 13.4 million in 2020, respectively. The United States Market Outlook This section provides the total MPA market size and market size by therapies in the United States. EU5 Market Outlook The total MPA market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section. Japan Market Outlook Scope of the Report The report covers the descriptive overview of MPA, explaining its causes, symptoms, pathogenesis, genetic basis, and currently available therapies. Comprehensive insight has been provided into the MPA epidemiology and treatment. Additionally, an all-inclusive account of both the current and emerging therapies for MPA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape. A detailed review of the MPA market; historical and forecasted is included in the report, covering the 7MM drug outreach. The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM MPA market. Report Highlights The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the MPA market. The companies and academics are working to assess challenges and seek opportunities that could influence MPA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players are involved in developing therapies for MPA. The approval of emerging therapies will significantly impact the MPA market. Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. Companies Mentioned

Zenyaku Kogyo Investments

4 Investments

Zenyaku Kogyo has made 4 investments. Their latest investment was in Theraclone Sciences as part of their Series B - IV on March 3, 2013.

CBI Logo

Zenyaku Kogyo Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/25/2013

Series B - IV

Theraclone Sciences

$8M

No

6

9/9/2011

Series B - III

Subscribe to see more

$99M

Subscribe to see more

10

3/22/2010

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

10/13/2009

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/25/2013

9/9/2011

3/22/2010

10/13/2009

Round

Series B - IV

Series B - III

Series B - II

Partnership

Company

Theraclone Sciences

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$8M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

10

10

10

Zenyaku Kogyo Partners & Customers

1 Partners and customers

Zenyaku Kogyo has 1 strategic partners and customers. Zenyaku Kogyo recently partnered with Anthera Pharmaceuticals on December 12, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

12/15/2014

Licensor

Anthera Pharmaceuticals

United States

Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku

HAYWARD , Calif. , Sept. 14 , 2015 -LRB- GLOBE NEWSWIRE -RRB- -- Anthera Pharmaceuticals , Inc. -LRB- : ANTH -RRB- today announced receipt of a termination notice from its development partner in Japan , Zenyaku Kogyo , terminating the December 2014 Collaboration and License Agreement -LRB- the `` License Agreement '' -RRB- effective January 7 , 2016 .

2

Date

12/15/2014

Type

Licensor

Business Partner

Anthera Pharmaceuticals

Country

United States

News Snippet

Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku

HAYWARD , Calif. , Sept. 14 , 2015 -LRB- GLOBE NEWSWIRE -RRB- -- Anthera Pharmaceuticals , Inc. -LRB- : ANTH -RRB- today announced receipt of a termination notice from its development partner in Japan , Zenyaku Kogyo , terminating the December 2014 Collaboration and License Agreement -LRB- the `` License Agreement '' -RRB- effective January 7 , 2016 .

Sources

2

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.